
Coloplast
CLPBY | OTC
$7.46
-$0.03 (-0.40%)
At close: Nov 16, 2026, 3:58 PM ET
$7.46
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 3:58 PM ET
Coloplast Company Profile
Company profile explainedCompany Profile
Coloplast A/S, founded in 1954 and headquartered in Humlebæk, Denmark, operates as a global developer and marketer of intimate healthcare products and services. Its extensive reach spans Denmark, the United States, the United Kingdom, France, and numerous other international regions. The company's activities are organized into three primary segments: Chronic Care, Interventional Urology, and Wound & Skin Care. Within Chronic Care, Coloplast provides advanced ostomy solutions, including the SenSura Mio, recognized for its adaptable fit and discretion, alongside other SenSura offerings and Brava brand accessories. This segment also delivers continence care products such as Conveen Active urine bags, SpeediCath catheters for diverse users, and the Peristeen transanal irrigation system. The Wound & Skin Care division features innovative dressings like the conforming Biatain Silicone and the hydrocolloid Comfeel. Additionally, it offers a broad spectrum of skin care items, encompassing bathing and cleansing products, moisturizers, skin protectants, antifungal treatments, hand cleansers, odor control solutions, and the specialized InterDry system for managing skin folds. Finally, the Interventional Urology segment is dedicated to crafting and commercializing surgical devices that address a range of urological and gynecological conditions, such as urinary stone disease, benign prostatic hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence.
Key Executives
| Name | Position |
|---|---|
| Gavin Wood | President & Chief Executive Officer |
| Amanda Rajkumar | Executive VP & Chief People Officer |
| Anders Lonning-Skovgaard | Executive Vice President & Chief Financial Officer |
| Alain Morvan | Senior Vice President of Sales Europe |
| Aleksandra Dimovska | Vice President of Investor Relations |
| Allan Rasmussen | Executive Vice President of Global Operations |
| Caroline Vagner Rosenstand | Executive Vice President of Chronic Care Commercial |
| Dennis Kaysen | Vice President of Corporate Communications |
| Mads Mikkelsen | VP of People & Culture - Chronic Care Commercial and Interim Head of Global People & Culture |
| Nicolai Buhl Andersen | Executive Vice President of Chronic Care |
| Rasmus Hannemann Møller | Senior Vice President of Wound & Skin Care |
| Thomas Barfod | Senior Controller & Employees Representative Director |
Coloplast

| Country | Denmark |
| IPO Date | Jan 13, 2014 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 16,907 |
| CEO | Gavin Wood |
Stock Details
| Ticker Symbol | CLPBY |
| Exchange | OTC |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001294325 |
| CUSIP Number | 19624Y200 |
| ISIN Number | US19624Y2000 |
| SIC Code |
Recent News
- 6 days ago / seekingalpha.comColoplast: Turnaround Is Underway, But Upside Is Limited
- 14 days ago / seekingalpha.comColoplast A/S (CLPBY) Q4 2026 Earnings Call Transcript
- 14 days ago / reuters.comColoplast pares back China operations as market recovery remains elusive
- 3 months ago / seekingalpha.comColoplast A/S (CLPBY) Q3 2026 Earnings Call Transcript
- 3 months ago / reuters.comColoplast expects Kerecis wound-care unit to return to growth in 2027, CFO says
- 3 months ago / seekingalpha.comColoplast Might Have Found Its Bottom
Add to Watchlist
Select watchlists to add or remove CLPBY